Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.
2021 and 2020 Milestones In Plain Sight.
Locked and Loaded for most of 2020 - many major milestone...
Citius Pharma (CTXR) Video Presentation.
Chairman Leonard Mazur Discusses:
Mino-Lok Treatment for Infected Catheters.
Novellus Stem Cell Treatment...
Immunomedics (IMMU) $3.00 to $88, Up 29-fold, Our Second Best Idea Ever.
Interesting Charts From the Day we Discovered it.
Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced...
American BriVision’s (ABVC) Clinical Study Sparks Interest From Potential Partners.
Is Wall Street Missing American Brivision's Full Clinical Safety and Efficacy Study? We Think it has.
Potential...
There’s Simply No Loyalty Anymore.
TODAY'S LETTER
Frontier Bio (FBIO) $3.90. We Have Another Double! American BriVision (ABVC) $4.00. Wait, What? Yet...
And We Have Another Double. Frontier Bio (FBIO) Crosses $4.00.
Sometimes we Can't Beleive Our Luck Over the Last Couple Years. But There You Have it, at Least we Know It's...
American BriVision’s (ABVC) Novel Polygala Plant Extract, for the Treatment of Clinical Depression.
American BriVision Announces New Patent Filed for Treatment of Major Depressive Disorder.
Phase II clinical study completed at...
Investors Bet $8 Million on Citius Pharma (CTXR) $1.10, Succeeding in FDA Trials!
Great headline, right?
The actual headline was: Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 Million
American BriVision (ABVC) Reports Completion Clinical Trial for Treatment of Adult ADHD.
American BriVision (ABVC) Reports Completion of ABV-1505 Phase II Part I Clinical Trial for Treatment of Adult ADHD.
Last...
Latest article
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
